Patents Assigned to Wyeth
  • 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20090192176
    Abstract: The invention relates to 1H-pyrazolo[3,4-d]pyrimidine, purine, 7H-purin-8(9H)-one, 3H-[1,2,3]triazolo[4,5-d]pyrimidine, and thieno[3,2-d]pyrimidine compounds, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: January 29, 2009
    Publication date: July 30, 2009
    Applicant: Wyeth
    Inventors: Arie Zask, Christoph Martin Dehnhardt, Joshua Aaron Kaplan, Efren Guillermo Delos Santos, Aranapakam Mudumbai Venkatesan, Jeroen Cunera Verheijen
  • [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20090192147
    Abstract: The invention relates to [a]-fused indole compounds of the Formula II, or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein. The invention also relates to compositions comprising the compounds of Formula II, and methods for making and using the compounds.
    Type: Application
    Filed: January 30, 2009
    Publication date: July 30, 2009
    Applicant: Wyeth
    Inventors: Semiramis Ayral-Kaloustian, Nan Zhang, Aranapakam Mudumbai Venkatesan, Tarek Suhayl Mansour, Thai Hiep Nguyen, James Thomas Anderson
  • Nucleic acid and amino acid sequences relating to for diagnostics and therapeutics
    Patent number: 7566776
    Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: July 28, 2009
    Assignee: Wyeth
    Inventors: Lynn Doucette-Stamm, David Bush
  • Substituted 3-carbonyl--indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    Patent number: 7566791
    Abstract: Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives of formula I are provided: wherein: R1, R2, R3, R4 and R5 are as defined herein which are useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) for treating conditions resulting from fibrinolytic disorders, such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: July 28, 2009
    Assignee: Wyeth
    Inventor: Lee D. Jennings
  • Pathway Analysis of Cell Culture Phenotypes and Uses Thereof
    Publication number: 20090186358
    Abstract: The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 23, 2009
    Applicants: Wyeth, Dublin City University
    Inventors: Mark Melville, Niall Barron, Martin Clynes, Padraig Doolan, Patrick Gammell, Paula Meleady
  • EPHRIN AND EPH RECEPTOR AGONISTS FOR MODULATION OF BONE FORMATION AND RESORPTION
    Publication number: 20090186026
    Abstract: Compositions that stimulate bone formation and inhibit bone resorption through activation of both arms of EphrinB2-EphB4 signaling are provided. The composition comprises a bi-functional molecule having at least one EphB4 ligand-binding domain conjugated to an anti-EphB4 antibody.
    Type: Application
    Filed: January 16, 2009
    Publication date: July 23, 2009
    Applicant: Wyeth
    Inventors: Julia Billiard, Lioudmila Tchistiakova
  • Triazole derivatives and method of using the same to treat HIV infections
    Patent number: 7563905
    Abstract: The present invention is directed to compounds of formula (I): wherein R1, R2 and R3 are independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl and X1 and X2 are independently a bond or an linker group of 1 to 6 atoms and may be optional substituted or oxidized, or a prodrug, a pharmaceutically acceptable salt or a pharmaceutically active metabolite thereof. The invention is also directed to methods of using the same for treating HIV infections, or AIDs or preventing viral replication.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: July 21, 2009
    Assignee: Wyeth
    Inventors: Matthew Olson, Martin Di Grandi
  • Iminothiazolidinone derivatives as SFRP-1 antagonists
    Patent number: 7563813
    Abstract: Compounds of Formula 1, or pharmaceutically acceptable salts thereof, are provided: which are inhibitors of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: July 21, 2009
    Assignee: Wyeth
    Inventors: Ariamala Gopalsamy, Mengxiao Shi
  • Process for preparation of phenethylamine derivatives
    Patent number: 7563931
    Abstract: A process for the preparation of a compound of formula I, wherein R1 and R2 are ortho or para substituents, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C7-C9 aralkoxy, C2-C7 alkanoyloxy, C1-C6 alkylmercapto, halo and trifluoromethyl; R3 is hydrogen or C1-C6 alkyl; R4 is hydrogen, C1-C6 alkyl, formyl or C2-C7 alkanoyl; n is one of the integers 0, 1, 2, 3 or 4; and the dotted line represents optional olefinic unsaturation; comprising hydrogenating a compound of formula III, in the presence of a nickel or cobalt catalyst at a temperature of about 5° C. to 25° C.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: July 21, 2009
    Assignee: Wyeth
    Inventors: Keun-Sik Kim, Kwang-Il Kim, Ki-Byung Chai
  • Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
    Patent number: 7563793
    Abstract: This invention provides estrogen receptor modulators having the structure: wherein R1 to R7, R9, R10, X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: July 21, 2009
    Assignee: Wyeth
    Inventors: Joseph Peter Sabatucci, Fei Ye, Paige Erin Mahaney
  • Diphenylimidazopyrimidines as inhibitors of ?-secretase
    Patent number: 7563796
    Abstract: The present invention provides an amino-imidazolone compound of formula I Also provided are compositions and methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: July 21, 2009
    Assignee: Wyeth
    Inventors: Michael Sotirios Malamas, James Joseph Erdei, Iwan Suwandi Gunawan, Pawel Wojciech Nowak, Boyd Lynn Harrison
  • 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20090181963
    Abstract: The invention relates to 3H-[1,2,3]triazolo[4,5-d]pyrimidine compounds of the Formula 1: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: January 15, 2009
    Publication date: July 16, 2009
    Applicant: Wyeth
    Inventors: Christoph Martin Dehnhardt, Aranapakam Mudumbai Venkatesan, Efren Guillermo Delos Santos, Zecheng Chen, Osvaldo Dos Santos, Natasja Brooijmans, Arie Zask, Jeroen Cunera Verheijen, Semiramis Ayral-Kaloustian
  • COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS
    Publication number: 20090181932
    Abstract: A synthetic compound characterized by having the structure of formula I or II or a pharmaceutically acceptable salt and/or hydrate thereof is provided. Formula I and formula II are defined as follows. wherein R1 is substituted aryl or substituted heteroaryl; R2 and R3 are independently selected from the group consisting of CF3, substituted phenyl, C1-C4 alkyl, substituted C1-C4 alkyl, (CF3)nC1-C4alkyl, (CF3)n(substituted C1-C4 alkyl), provided that when R2 or R3 is CF3, the other is not an unsubstituted alkyl; R4 and R4? are independently selected from the group consisting of M, C1-C4 alkyl, phenyl, and benzyl, wherein M is a metal ion is selected from the group consisting of sodium, lithium, calcium, magnesium and potassium, or R4 and R4? are taken together to form a cyclic structure. Methods of making such compounds and uses thereof are also provided.
    Type: Application
    Filed: January 7, 2009
    Publication date: July 16, 2009
    Applicant: Wyeth
    Inventors: David Zenan LI, Dane Springer, Sayed Elmarakby, Appavu Chandrasekaran, Anthony F. Kreft, III
  • COMPOUND FORMS AND USES THEREOF
    Publication number: 20090181953
    Abstract: The present invention provides, among other things, forms of a compound of formula 1. In some embodiments, the present invention provides salt forms and/or crystal forms. In some embodiments, the present invention provides solid forms. The present invention also provides methods of making and using provided forms.
    Type: Application
    Filed: January 14, 2009
    Publication date: July 16, 2009
    Applicants: WYETH, SIENA BIOTECH S.P.A.
    Inventors: Mahmoud Mirmehrabi, Abdolsamad Tadayon, Subodh Deshmukh, Arianna Nencini, Riccardo Zanaletti
  • COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20090181952
    Abstract: The present invention provides compounds and compositions, and methods of using them to modulate ?7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.
    Type: Application
    Filed: January 14, 2009
    Publication date: July 16, 2009
    Applicants: Wyeth, Siena Biotech S.p.A.
    Inventors: Simon N. Haydar, Riccardo Zanaletti
  • Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
    Patent number: 7560470
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 14, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan, Albert Jean Robichaud, Guangcheng Liu
  • Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
    Patent number: 7560457
    Abstract: The present invention provides compounds of the following structure, wherein R1, R2, R4, R4?, R6, R7, and R15 are defined above: These compounds are useful in treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: July 14, 2009
    Assignee: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
  • Modified and stabilized GDF propeptides and uses thereof
    Patent number: 7560441
    Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: July 14, 2009
    Assignee: Wyeth
    Inventors: Neil M. Wolfman, Soo-Peang Khor, Kathleen N. Tomkinson
  • PHARMACEUTICAL SUSPENSION COMPOSITION
    Publication number: 20090176884
    Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
    Type: Application
    Filed: March 12, 2009
    Publication date: July 9, 2009
    Applicant: Wyeth
    Inventors: Jay Dickerson, William Mark, Annabelle Trimmer, David Jaeger, Amanda Roop Alley
  • COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION
    Publication number: 20090176720
    Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
    Type: Application
    Filed: February 13, 2009
    Publication date: July 9, 2009
    Applicant: Wyeth Holdings Corporation
    Inventors: Jonathan Marc Cohen, Syed Muzafar Shah, Christian Luther Ofslager, Mahdi Bakir Fawzi